MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 19, Issue 22, 2001, Pages 4259-4266

  Ramnath, N ^a   Hernandez, F J ^a   Tan, D F ^a   Huberman, J A ^a   Natarajan, N ^a   Beck, A F ^a   Hyland, A ^a   Todorov, I T ^a   Brooks, J S J ^a   Bepler, G ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; DNA REPLICATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MINICHROMOSOME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0035890436     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.22.4259     Document Type: Article

References (43)

1. Changing patterns of lung cancer incidence by histological type
2. Cancer statistics, 2000
3. Cancer statistics, 1998
4. Early detection and screening for lung cancer
5. Revisions in the international system for staging lung cancer
6. Treatment of stage I and II disease
7. Angiogenesis and molecular biologic sub-staging in patients with stage I non-small-cell lung cancer
8. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
9. 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases
10. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung
11. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small-cell lung cancer: A preliminary report of LCSG 871
12. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
13. Alterations of expression of rb, pl6(INK4A) and cyclin D1 in non-small-cell lung carcinoma and their clinical significance
14. Cellular predictive factors for the drug response of lung cancer
15. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy
16. Expression of plasminogen activator inhibitors I and 2 in lung cancer and their role in tumor progression
17. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and poidy in surgically resected non-small-cell lung cancers
18. Do molecular markers predict survival in non-small-cell lung cancer?
19. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small-cell lung cancer: A Cancer and Leukemia Group B study
20. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small-cell lung cancer
21. Prognostic significance of different biomarkers in non-small-cell lung cancer
22. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small-cell lung carcinoma
23. The Ki-67 protein: Fascinating forms and an unknown function
24. Properties of the nuclear Pprotein, a mammalian homologue of the yeast MCM3 replication protein
25. The role of MCM proteins in the cell cycle control of genome duplication
26. Mechanisms resticting DNA replication to once per cell cycle: The role of CDC and ORC
27. Tye BK: MCM proteins in DNA replication
28. Uninterrupted MCM2-7 function required for DNA replication fork progression
29. HsMCM2/BM28: A novel proliferation marker for human tumors and normal tissues
30. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy
31. MCM2: A promising marker for premalignant lesions of the lung - A cohort study
32. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication
33. Epidemiology of tobacco use and dependence
34. Clone 10d/BM28 (CDCLI), an early S-phase protein, is an important growth regulator of melanoma
35. MCM2 and MCM3 are consitutive nuclear proteins that exhibit distinct isoforms and bind chromatin during specific cell cycle stages of Saccharomyces cerevisiae
36. Physical interactions among MCM proteins and effects of MCM dosage on DNA replication in Saccharomyces cerevisiae
37. Chemotherapy of non-small-cell lung cancer: A randomized trial of cisplatin/vindesine versus no chemotherapy
38. Chemotherapy can prolong survival on patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial
39. Supportive care versus supportive care and combination chemotherapy in metastatic non-small-cell lung cancer
40. Polychemotherapy in advanced non-small-cell lung cancer: A meta-analysis
41. A randomized phase III trial in metastatic non-small-cell lung cancer: An Eastern Cooperative Group Trial (ECOG 1594)
42. A prognostic model or recurrence and death in stage I non-small-cell lung cancer utilizing presentation, histopathology, and oncoprotein expression